Arcus Biosciences (RCUS) Competitors $11.33 -0.11 (-1.00%) Closing price 03:59 PM EasternExtended Trading$11.31 -0.02 (-0.18%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. ACAD, KRYS, CYTK, MENS, ADMA, PCVX, AAPG, PTCT, ACLX, and AKROShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), PTC Therapeutics (PTCT), Arcellx (ACLX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Its Competitors ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Ascentage Pharma Group International PTC Therapeutics Arcellx Akero Therapeutics Arcus Biosciences (NYSE:RCUS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Does the media prefer RCUS or ACAD? In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 19 mentions for ACADIA Pharmaceuticals and 17 mentions for Arcus Biosciences. ACADIA Pharmaceuticals' average media sentiment score of 1.36 beat Arcus Biosciences' score of 1.06 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 12 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer RCUS or ACAD? Arcus Biosciences presently has a consensus target price of $21.14, indicating a potential upside of 86.68%. ACADIA Pharmaceuticals has a consensus target price of $29.06, indicating a potential upside of 17.00%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Arcus Biosciences is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.61 Is RCUS or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Arcus Biosciences' net margin of -109.56%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-109.56% -55.96% -25.73% ACADIA Pharmaceuticals 21.80%14.69%9.41% Which has more risk and volatility, RCUS or ACAD? Arcus Biosciences has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Which has stronger valuation and earnings, RCUS or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$258M4.67-$283M-$3.17-3.57ACADIA Pharmaceuticals$957.80M4.38$226.45M$1.3318.68 Do institutionals & insiders believe in RCUS or ACAD? 92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryACADIA Pharmaceuticals beats Arcus Biosciences on 13 of the 17 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesMED IndustryMedical SectorNYSE ExchangeMarket Cap$1.22B$3.17B$5.81B$21.33BDividend YieldN/A2.28%5.29%3.49%P/E Ratio-3.5721.3475.6929.42Price / Sales4.67469.04539.3668.71Price / CashN/A45.5837.2024.61Price / Book2.1410.0511.504.55Net Income-$283M-$53.33M$3.28B$999.91M7 Day Performance4.82%2.18%1.30%0.84%1 Month Performance24.67%11.91%11.25%5.23%1 Year Performance-30.64%14.14%59.54%16.62% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences2.1738 of 5 stars$11.33-1.0%$21.14+86.7%-27.3%$1.22B$258M-3.57500News CoveragePositive NewsACADACADIA Pharmaceuticals4.2946 of 5 stars$25.99-0.9%$28.88+11.1%+58.0%$4.38B$957.80M19.54510News CoveragePositive NewsAnalyst ForecastKRYSKrystal Biotech4.8857 of 5 stars$147.70-2.0%$210.38+42.4%-21.2%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.0638 of 5 stars$35.33-5.4%$71.58+102.6%-3.7%$4.23B$18.47M-6.93250MENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031ADMAADMA Biologics3.6341 of 5 stars$17.26-0.7%$27.67+60.3%+1.0%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.7071 of 5 stars$30.79+0.1%$136.50+343.3%-71.0%$4.00BN/A-7.49160Positive NewsAAPGAscentage Pharma Group InternationalN/A$42.47+3.3%N/AN/A$3.95B$134.35M0.00600Positive NewsPTCTPTC Therapeutics3.9359 of 5 stars$49.33-0.9%$69.15+40.2%+80.6%$3.92B$806.78M7.081,410Insider TradeACLXArcellx2.6319 of 5 stars$69.39-1.2%$114.31+64.7%-0.2%$3.85B$107.94M-20.2980Positive NewsAKROAkero Therapeutics3.8938 of 5 stars$46.73-0.4%$81.57+74.6%+68.8%$3.74BN/A-23.3730Positive NewsAnalyst Revision Related Companies and Tools Related Companies ACADIA Pharmaceuticals Competitors Krystal Biotech Competitors Cytokinetics Competitors Jyong Biotech Competitors ADMA Biologics Competitors Vaxcyte Competitors Ascentage Pharma Group International Competitors PTC Therapeutics Competitors Arcellx Competitors Akero Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCUS Stock Alerts